Skip to content

About Neuromod

Neuromod Devices Ltd is a medical technology company specialising in the design and development of neuromodulation technologies to address the clinical needs of those with tinnitus.

Read the latest news about Neuromod and Lenire
Neuromod Team around a table

About Neuromod

Founded in 2010, Neuromod Devices Ltd is a medical technology company headquartered in Dublin, Ireland. Neuromod specialises in the design and development of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions.

The lead application of Neuromod’s technology is in the field of tinnitus, where Neuromod has completed extensive clinical trials to confirm the efficacy of Lenire, its non-invasive bimodal neuromodulation device, for treating this common disorder. Neuromod’s tinnitus treatment device, Lenire is currently available in Ireland and throughout Europe.

Origin of Neuromod and Lenire

Neuromod Devices was founded by Dr Ross O’Neill in 2010 as a spin-out from Maynooth University to develop innovative neuromodulation technologies for the treatment of unaddressed neurological conditions, namely tinnitus.

Dr O’Neill had developed an interest in tinnitus during his PhD research at Maynooth in biomedical engineering and he was surprised at how few treatment options existed for a health condition suffered by an estimated 300 million people worldwide, affecting between 10-15% of the global population, according to the WHO.

What piqued O’Neill’s interest in this condition were conversations he had with people who had been profoundly affected by tinnitus.

the lenire device package

During these conversations, O’Neill could tell that their tinnitus was causing these people a considerable amount of distress. It was having a negative impact on everyday things we all take for granted, such as concentrating at work or getting a good night’s sleep.

He also noted that the clinical journey for tinnitus patients was frustrating. Patients tended to get passed from their GP to an ENT (Ear, Nose and Throat) and to an Audiologist and often back again with very poor clinical outcomes.

As part of his doctoral research, O’Neill had been investigating the interaction between the auditory and somatic nervous systems, and how the field of neuromodulation could be applied to these systems to potentially treat tinnitus. Following the completion of his PhD, he formed the company Neuromod Devices to develop the technology.

Neuromod secured a number of grants and seed funding to help with the design, development of a medical device to treat tinnitus, as well as funding safety and feasibility studies.

O’Neill later became familiar with the work of Prof. Hubert Lim in the University of Minnesota. Prof. Lim had done extensive research on how the hearing parts of brain react to stimulation of the tongue and ear. O’Neill, based in Dublin, Ireland, approached Prof. Lim, proposing that the two researchers collaborate to accelerate the development of the technology. Prof. Lim, who was a translational scientist whose focus was bringing the bimodal neuromodulation to the millions of tinnitus patients whose clinical needs were so poorly served, agreed and joined the company as Chief Scientific Officer.

Neuromod had already attracted the attention of Fountain Healthcare Partners, a venture capital fund, who invested and enabled the company to conduct two of the largest and longest-followed-up clinical trials ever conducted in tinnitus under the guidance of the company’s Science Advisory Board, which includes three of the top international key opinion leading scientists in the field. The investment also allowed the scale up production and establishment of an expert leadership team.

clinical trial with tinnitus patient

Scientific Advisory Board

Neuromod collaborates with opinion-leading scientists and clinicians to conduct large-scale exploratory and confirmatory trials at internationally recognised clinical sites to build the evidence base for our interventions. Neuromod’s bimodal neuromodulation technology for the treatment of chronic tinnitus has undergone large-scale trials across a number of European clinical sites under the guidance and supervision of our Science Advisory Board.

Advisory Board Members

Prof. Berthold Langguth
University of Regensburg

Berthold Langguth is a Consultant Neuropsychiatrist who runs the Department of Psychiatry and Psychosomatic Medicine at Germany’s University of Regensburg Hospital (UHREG), which he has established as a leading European site for clinical trials and tinnitus research.

Prof. Langguth is an international key opinion leader in the field of tinnitus research with over 300 peer-reviewed publications and book chapters. A key focus area of research is patient subtyping and neuromodulation.

Prof. Langguth is the founder of the Tinnitus Research Initiative (TRI), a non-profit organisation that brings together tinnitus scientists from across the globe is dedicated to the development of effective treatments for all types of tinnitus.

Prof. Sven Vanneste
Trinity College Dublin / University of Texas

Sven Vanneste is Professor of Neurosciences at Trinity College Dublin (TCD) in Ireland and the University of Texas at Dallas in the USA.

A leading voice in the field of neuromodulation research, with over 250 peer-reviewed publications and book chapters, Prof. Vanneste has established a neuromodulation research laboratory that has become a leading neuromodulation research centre globally.

Prof. Vanneste has collaborated on invasive and non-invasive neuromodulation trials for the Enterprise Ireland, the Health Research, Board, US Department of Defence (US-DoD), the US National Institutes for Health (NIH) and the US Food and Drug Administration (FDA) for neuromodulation start-ups and large medical device multinationals.

Prof. Deborah Hall
Heriot-Watt University Malaysia

Deborah Hall is currently Head of the Department of Psychology at Heriot-Watt University Malaysia where she holds an appointment as Professor of Positive Psychology. Prior to this she led active tinnitus and translational neuroscience research teams at the University of Nottingham, UK and was Deputy Director of the National Institute for Health Research Nottingham Biomedical Research Centre.

In the fields of clinical trial methodologies and evidence-based medicines, Prof. Hall is highly regarded internationally, with over 100 peer-reviewed publications and book chapters. She was awarded the British Society of Audiology Thomas Simm Littler Prize in 2010 for her services to audiology, and is the Editor of ‘Hearing Research’, one of the highest impact factor journals in the world of auditory research.

Neuromod Leadership Team

Our management and board share a commitment towards achieving significant breakthroughs in the field of bi-modal neuromodulation. Together, we bring our collective skills, talents and experience to bear on the pursuit of this ambitious endeavour.

Our team includes ear, nose and throat (ENT) surgeons, neuroscientists, audiologists, clinicians, engineers, regulatory experts, product designers and others who are instrumental to our vision of realising the untapped potential of neuromodulation in medicine.

Dr. Ross O’Neill PhD MBA
Founder & CEO

Mr. Brendan Conlon PhD
Chief Medical Officer

Dr. Hubert Lim PhD
Chief Scientific Officer

Florian Elsaesser
Chief Strategy & Corporate Development Officer

Diarmuid Flavin
Chief Operating Officer
Derek Madden CPA CTax
Chief Financial Officer

Caroline Hamilton BSc (Aud), MSc (Neuro)
Audiology Director
Dr. Tish Ramirez
Chief Commercial Officer, Neuromod USA
Eric Timm
President, Global Commercial Operations & Chief Executive Officer, Neuromod USA
Stephanie Glowacki
Chief Financial Officer, Neuromod USA

Find a Clinic Near You

Your treatment with Lenire begins with an audiological and tinnitus assessment by a qualified healthcare professional. Our partners are trained to prescribe a treatment plan with Lenire specifically for your tinnitus. Find a Lenire partner clinic to take the first step towards managing your tinnitus.

Find a Clinic